Humacyte appoints Lt. Gen. Bruce Green to board and Cindy Cao as CRO

Humacyte, Inc.

Green, former U.S. Air Force Surgeon General, joins Board as Class I director.
Cao appointed Chief Regulatory Officer; prior SVP at Ascentage Pharma and roles at BMS, Novartis.
Outgoing CRO Bill Tente remains as Executive Advisor on regulatory initiatives.
Green receives $50K annual cash retainer (pro-rated) and option for 13,000 shares.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

C. Bruce Green

Director

HUMA · Humacyte, Inc.

Effective: 2022-09-15
Filed: September 20, 2022, 7:59 PM ET

On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

C. Bruce Green was appointed as Director at Humacyte, Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board.

View on SEC.gov

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-22-000172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.